Korea's chemical company SK Discovery Co. on Tuesday said it launched a bio strategy and investment division headed by Kim Jung-hoon, director of SK Chemicals' R&D center.
The new division will search for new business opportunities for SK Discovery's bio affiliates under the goal of creating horizontal expansion and a synergistic effect through inter-subsidiary collaboration.
A pharmaceutical and bio expert who joined SK Chemicals in 1998 after graduating from the College of Pharmacy at Seoul National University, Kim is experienced in leading overseas business, marketing and R&D organizations at the company.
"SK Discovery's bio affiliates have growth engines thanks to their outstanding human resources and business portfolios," Kim said. "The Bio Strategy and Investment Division will assume a role in fueling each affiliate's growth and creating a synergistic effect."
Write to Jeong Min Nam at peux@hankyung.com
SK Biopharm researchers South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medication's sales in the first three quarters hit 119.4 billion won ($89 million), with the third quarter alone seeing growth o
SK Bioscience’s production line of SKYCovione in South Korea (Courtesy of Yonhap) SK Bioscience Co., the biopharmaceutical unit of South Korea’s No. 2 conglomerate SK Group, sought approval from the World Health Organization (WHO) for the immediate sale of the company’s COVID-
An SK Bioscience researcher SK Discovery Co., an intermediate holding company of South Korea’s third-largest conglomerate SK Group, will take charge of the entire biotechnology and pharmaceutical businesses at its affiliates for efficient management.According to industry officials on Thur
SK is the latest Korean conglomerate to announce huge investment plans SK Group, South Korea’s second-largest conglomerate after Samsung, on Thursday announced a plan to invest 247 trillion won ($195 billion) in key growth sectors such as semiconductors, batteries and biotechnology over t